{
    "clinical_study": {
        "@rank": "116095", 
        "arm_group": [
            {
                "arm_group_label": "ASP4901 group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Tamsulosin group", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy of ASP4901 with placebo in patients\n      with benign prostatic hyperplasia.  The safety and tolerability of ASP4901 will also be\n      evaluated."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Benign Prostate Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, randomized, parallel-group, placebo-controlled, active-referenced,\n      double-blind study. After obtaining the written consent, patients meeting the eligibility\n      criteria at the preliminary enrollment will receive oral administration of placebo in a\n      single-blinded manner (single-blind placebo run-in period). Then, patients meeting the\n      eligibility criteria at the main enrollment will receive drug or placebo (double-blind\n      treatment period) for 4 weeks. Furthermore, patients will be followed up for 1 week to\n      confirm the safety of the study drugs after the treatment period (safety follow-up period)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  dysuria associated with BPH for at least 12 weeks before providing consent\n\n          -  a total IPSS core of 13 or higher\n\n          -  a QOL score of 3 or higher\n\n          -  a maximum urinary flow rate (Qmax) of \u22654 mL/sec and <15 mL/sec.\n\n          -  a prostate volume of \u226520 mL.\n\n        Exclusion Criteria:\n\n          -  A postvoid residual volume (PVR) of >350 mL\n\n          -  A previous or concurrent symptomatic urinary tract infection within 4 weeks of the\n             study\n\n          -  A cataract operation scheduled to be performed during the study period\n\n          -  Previous or concurrent clinically relevant cardiovascular or cerebrovascular disorder\n             within 24 weeks prior to the study\n\n          -  Hypersensitivity to ASP4901 or tamsulosin hydrochloride\n\n          -  Presence of serious hepatic diseases, renal diseases, immunological diseases, or\n             pulmonary diseases that are clinically relevant"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038868", 
            "org_study_id": "4901-CL-0201"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP4901 group", 
                "description": "oral", 
                "intervention_name": "ASP4901", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tamsulosin group", 
                "description": "oral", 
                "intervention_name": "Tamsulosin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "YM617", 
                    "Harnal"
                ]
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tamsulosin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "BPH", 
            "ASP4901"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Double-Blind, Placebo-Controlled, Active-Referenced, Parallel-Group Comparative Study in Patients With Benign Prostatic Hyperplasia", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline  in total IPSS (International Prostate Symptom Score)", 
            "safety_issue": "No", 
            "time_frame": "baseline and at the final evaluation (up to 5 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in each symptom score of IPSS", 
                "safety_issue": "No", 
                "time_frame": "baseline and at the final evaluation  (up to 5 weeks)"
            }, 
            {
                "measure": "Change from baseline in IPSS QOL (quality of life) score", 
                "safety_issue": "No", 
                "time_frame": "baseline and at the final evaluation (up to 5 weeks)"
            }, 
            {
                "description": "\"IPSS responder\" is defined as 25% improvement in IPSS", 
                "measure": "Proportion of IPSS responder", 
                "safety_issue": "No", 
                "time_frame": "baseline and at the final evaluation (up to 5 weeks)"
            }, 
            {
                "description": "only for ASP4901 group", 
                "measure": "Plasma concentration of ASP4901", 
                "safety_issue": "No", 
                "time_frame": "up to 5 weeks"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, labo-tests and 12-lead ECGs", 
                "safety_issue": "No", 
                "time_frame": "up to 5 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}